CSL chairman Brian McNamee has made a spirited defence of the growth prospects of Australia’s premier biotech, after the company suffered a 23 per cent protest vote over executive pay at its annual meeting on Wednesday.

The $123 billion blood products giant has suffered close to a 25 per cent fall in its share valuation since a high of $336 in February 2020. New CEO Paul McKenzie succeeded Paul Perreault in March.